NARI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NARI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inari Medical has the Financial Strength Rank of 7.
Good Sign:
Inari Medical Inc shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.Inari Medical did not have earnings to cover the interest expense. Inari Medical's debt to revenue ratio for the quarter that ended in Dec. 2023 was 0.06. As of today, Inari Medical's Altman Z-Score is 7.24.
For the Medical Devices subindustry, Inari Medical's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Inari Medical's Financial Strength distribution charts can be found below:
* The bar in red indicates where Inari Medical's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Inari Medical's Interest Expense for the months ended in Dec. 2023 was $-0.1 Mil. Its Operating Income for the months ended in Dec. 2023 was $-9.3 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $30.4 Mil.
Inari Medical's Interest Coverage for the quarter that ended in Dec. 2023 is
Inari Medical did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Inari Medical's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
Debt to Revenue Ratio | = | Total Debt (Q: Dec. 2023 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (1.692 | + | 30.355) | / | 528.376 | |
= | 0.06 |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Inari Medical has a Z-score of 7.24, indicating it is in Safe Zones. This implies the Z-Score is strong.
Good Sign:
Altman Z-score of 7.24 is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inari Medical (NAS:NARI) Financial Strength Explanation
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
Inari Medical has the Financial Strength Rank of 7.
Thank you for viewing the detailed overview of Inari Medical's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
William Hoffman | director, officer: President and CEO | C/O INARI MEDICAL, INC., 9 PARKER, SUITE 100, IRVINE CA 92618 |
Mitch C. Hill, | officer: Chief Financial Officer | 1009 TENNYSON DRIVE, SOUTHLAKE TX 76902 |
Andrew Hykes | officer: Chief Operating Officer | C/O INARI MEDICAL, INC., 9 PARKER AVENUE, SUITE 100, IRVINE CA 92618 |
Thomas Tu | officer: Chief Medical Officer | C/O INARI MEDICAL, INC., 9 PARKER AVENUE, SUITE 100, IRVINE CA 92618 |
Donald B Milder | director | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Robert Keith Warner | director | C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656 |
Catherine M. Szyman | director | C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614 |
Cynthia L Lucchese | director | 7966 N. ILLINOIS STREET, INDIANAPOLIS IN 46260 |
Mead Dana G Jr. | director | 2750 SAND HILL ROAD, MENLO PARK CA 94025 |
Rebecca Chambers | director | 3052 ORCHARD DR., SAN JOSE CA 95134 |
Jonathan D Root | director | 2735 SAND HILL ROAD, MENLO PARK CA 94025 |
Cooperatieve Gilde Healthcare Iv U.a. | 10 percent owner | NEWTONLANN 51, UTRECHT P7 3508AB |
Kirk G. Nielsen | director, 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Gilde Healthcare Iv Management B.v. | 10 percent owner | NEWTONLAAN 91, UTRECHT P7 3584 BP |
Gilde Healthcare Holding B.v. | 10 percent owner | NEWTONLAAN 91, PO BOX 85067, 3508 UTRECHT P7 AB |
From GuruFocus
By Value_Insider Value_Insider • 11-03-2022
By GlobeNewswire • 11-27-2023
By Tiesvg Tiesvg • 12-21-2022
By Stock market mentor Stock market mentor • 02-07-2023
By Stock market mentor Stock market mentor • 01-10-2023
By Stock market mentor Stock market mentor • 01-12-2023
By Marketwired • 08-24-2023
By Marketwired • 08-02-2023
By Sydnee Gatewood • 02-28-2023
By GuruFocus Research • 11-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.